Stockscreener 앱 받기
15.30
4.14%
-0.66
시장 영업 전:
15.13
-0.17
-1.11%
전일 마감가:
$15.96
열려 있는:
$15.97
하루 거래량:
3.34M
Relative Volume:
0.86
시가총액:
$2.86B
수익:
순이익/손실:
$-451.71M
주가수익비율:
-4.7426
EPS:
-3.2261
순현금흐름:
$-462.19M
1주 성능:
-4.20%
1개월 성능:
-17.39%
6개월 성능:
-22.77%
1년 성능:
-0.97%
1일 변동 폭
$0.00
$0.00
1주일 범위
$15.28
$17.31
52주 변동 폭
$13.72
$27.30
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
15.30 | 2.86B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2026-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-06-26 | 개시 | TD Cowen | Buy |
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-25 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares. - Stock Titan
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
Certain Restricted Stock Units of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com
Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com
New Dyne hires receive stock tied to 278,100 shares - Stock Titan
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com Canada
Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com UK
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Baird Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Wall Street Slashes Dyne Therapeutics Targets After Novartis DM1 Trial Failure - finance.biggo.com
DYN Maintained by Morgan Stanley -- Price Target Lowered to $36 - GuruFocus
Dyne Therapeutics Shares Plummet After Novartis Phase 3 Trial Failure - Intellectia AI
Dyne Therapeutics CMO Kerr Douglas Sells 5,035 Shares Between $18.88 and $24.35 (NASDAQ: DYN) - Kalkine Media
DYN Downgraded by JP Morgan -- Price Target Lowered to $10.00 - GuruFocus
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says - Moomoo
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Yahoo Finance
DYN Maintains Rating by RBC Capital -- Price Target Lowered to $30 - GuruFocus
Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com Canada
Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com UK
Dyne Therapeutics falls 16% after Novartis DM1 trial failure raises doubts on RNA therapy success - Pluang
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha
RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Nigeria
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Stocktwits
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Australia
Dyne Therapeutics (DYN) officer plans $106K stock sale - Stock Titan
Dyne Therapeutics (Nasdaq: DYN) officer to sell 3,000 shares from RSUs - Stock Titan
Dyne Therapeutics (DYN) CCO’s tax sales leave 102,966 unvested RSUs - Stock Titan
Tax-driven stock sale by Dyne (DYN) medical chief - Stock Titan
Dyne Therapeutics (DYN) CEO sells shares to cover taxes - Stock Titan
Raymond James sets Dyne Therapeutics price targ... - Pluang
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling - Benzinga
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Yahoo Finance
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Nigeria
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Canada
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings - Investing News Network
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - rttnews.com
Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase I - GuruFocus
Dyne Therapeutics (DYN) Faces Market Pressure After Novartis DM1 - GuruFocus
Dyne Therapeutics (DYN) Faces Pressure After Novartis Trial Fail - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Yahoo Finance
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Australia
Dyne Therapeutics stock faces pressure after rival drug fails trial - Investing.com
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed - Yahoo Finance
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
다인 테라 주식 (DYN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cox John | CEO & President |
Sep 08 '26 |
Sale |
18.88 |
5,658 |
106,823 |
357,507 |
| Cox John | Officer |
Sep 08 '26 |
Proposed Sale |
18.88 |
5,658 |
106,844 |
0 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 08 '26 |
Sale |
18.88 |
185 |
3,493 |
152,897 |
| Kerr Douglas | Officer |
Sep 08 '26 |
Proposed Sale |
18.89 |
35 |
661 |
0 |
| Kerr Douglas | Chief Medical Officer |
Sep 08 '26 |
Sale |
18.88 |
1,290 |
24,355 |
162,564 |
| Kerr Douglas | Officer |
Sep 04 '26 |
Proposed Sale |
24.35 |
5,000 |
121,745 |
0 |
| Kerr Douglas | Chief Medical Officer |
Sep 04 '26 |
Sale |
24.35 |
3,745 |
91,191 |
163,854 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 04 '26 |
Sale |
24.35 |
900 |
21,915 |
153,082 |
| Atlas Venture Opportunity Fund | Shareholder |
Aug 14 '26 |
Proposed Sale |
25.96 |
322,465 |
8,371,191 |
0 |
| Rhodes Jason P | Director |
Aug 14 '26 |
Sale |
25.00 |
2,160,516 |
54,012,900 |
428,946 |
7.52%
자본화:
|
볼륨(24시간):